Rituximab in relapsing-remitting multiple sclerosis [3]

New England Journal of Medicine

Volumn 358, Issue 24, 2008, Pages 2645-2647

  Schrijver, Hans M ^a  

^a Westfries Gasthuis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL AORTA ANEURYSM; ANEURYSM SURGERY; ARTERY CATHETER; CLINICAL PRACTICE; COHORT ANALYSIS; CONFOUNDING VARIABLE; ENDOVASCULAR SURGERY; HUMAN; LETTER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PULMONARY ARTERY; IMMUNOLOGY; METABOLISM; MULTIPLE SCLEROSIS; NOTE; CROHN DISEASE; DRUG SAFETY; EVALUATION; FOOD AND DRUG ADMINISTRATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; OPPORTUNISTIC INFECTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REMISSION; RISK BENEFIT ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; CHEMICALLY INDUCED DISORDER;

CD19 ANTIGEN; CD20 ANTIGEN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; RITUXIMAB; NATALIZUMAB;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTIGENS, CD20; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;

EID: 45149111352     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc080557     Document Type: Letter

References (3)

1. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88.
2. FDA public health advisory: life-threatening brain infection in patients with systemic lupus erythematosus after Rituxan (rituximab) treatment. (Accessed May 23, 2008, at http://www.fda.gov/cder/drug/advisory/rituximab.htm.)
3. Berger JR, Koralnik IJN. Progressive multifocal leukoencephalopathy and natalizumab - unforeseen consequences. N Engl J Med 2005;353:414-6.